Ars Pharmaceuticals Inc | Small-cap | Healthcare
$13.50
-9.21%
| Ars Pharmaceuticals Stock Comparison:
Ars Pharmaceuticals vs VertexArs Pharmaceuticals vs RegeneronArs Pharmaceuticals vs Sarepta TherapeuticsArs Pharmaceuticals vs AdaptiveArs Pharmaceuticals vs ArcutisArs Pharmaceuticals vs S&P 500 | Market
TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Jun 2025

Income Metrics

Revenue 15.7M
Gross Profit 10.7M 68.29%
Operating Income -47.6M -302.95%
Net Income -44.9M -285.57%
EPS (Diluted) $-0.46

Balance Sheet Metrics

Total Assets 327.3M
Total Liabilities 98.3M
Shareholders Equity 229.0M
Debt to Equity 0.43

Cash Flow Metrics

Operating Cash Flow -40.1M
Free Cash Flow -40.8M

Revenue & Profitability Trend

Ars Pharmaceuticals Income Statement From 2020 to 2024

Metric20242023202220212020
Revenue i89.1M30.0K1.3M5.5M17.8M
Cost of Goods Sold i977.0K----
Gross Profit i88.2M----
Gross Margin % i98.9%0.0%0.0%0.0%0.0%
Operating Expenses
Research & Development i19.6M20.3M18.4M20.3M14.1M
Selling, General & Administrative i71.7M47.3M18.5M4.7M4.2M
Other Operating Expenses i-----
Total Operating Expenses i91.3M67.6M36.8M25.0M18.3M
Operating Income i-3.1M-67.5M-35.5M-19.5M-469.0K
Operating Margin % i-3.5%-225,066.7%-2,698.8%-353.3%-2.6%
Non-Operating Items
Interest Income i-----
Interest Expense i-----
Other Non-Operating Income11.4M13.2M834.0K-789.0K-596.0K
Pre-tax Income i8.3M-54.4M-34.7M-20.2M-1.1M
Income Tax i288.0K----
Effective Tax Rate % i3.5%0.0%0.0%0.0%0.0%
Net Income i8.0M-54.4M-34.7M-20.2M-1.1M
Net Margin % i9.0%-181,216.7%-2,635.4%-367.7%-6.0%
Key Metrics
EBITDA i-3.1M-67.5M-35.1M-19.2M-463.0K
EPS (Basic) i$0.08$-0.57$-0.87$-0.22$-0.01
EPS (Diluted) i$0.08$-0.57$-0.87$-0.22$-0.01
Basic Shares Outstanding i9693666195215322399560439377016593770165
Diluted Shares Outstanding i9693666195215322399560439377016593770165

Income Statement Trend

Ars Pharmaceuticals Balance Sheet From 2020 to 2024

Metric20242023202220212020
Assets
Current Assets
Cash & Equivalents i50.8M71.0M210.5M60.1M24.5M
Short-term Investments i263.2M157.4M63.9M0-
Accounts Receivable i8.2M--0380.0K
Inventory i5.2M----
Other Current Assets1.2M163.0K---
Total Current Assets i334.3M231.7M277.7M60.7M26.4M
Non-Current Assets
Property, Plant & Equipment i987.0K945.0K822.0K707.0K31.0K
Goodwill i7.7M617.0K0--
Intangible Assets i7.7M617.0K---
Long-term Investments-----
Other Non-Current Assets5.3M-3.0M23.0K2.0K
Total Non-Current Assets i16.9M1.5M3.7M716.0K25.0K
Total Assets i351.2M233.2M281.4M61.4M26.4M
Liabilities
Current Liabilities
Accounts Payable i9.9M759.0K1.7M1.8M1.2M
Short-term Debt i42.0K237.0K230.0K3.6M2.6M
Current Portion of Long-term Debt-----
Other Current Liabilities-----
Total Current Liabilities i23.4M2.4M5.4M8.2M8.2M
Non-Current Liabilities
Long-term Debt i037.0K251.0K5.4M7.5M
Deferred Tax Liabilities i-----
Other Non-Current Liabilities69.4M---27.0K
Total Non-Current Liabilities i70.9M37.0K3.1M84.5M32.2M
Total Liabilities i94.4M2.4M8.5M92.7M40.5M
Equity
Common Stock i10.0K10.0K9.0K3.0K223.0K
Retained Earnings i-123.3M-131.3M-76.9M-42.3M-22.0M
Treasury Stock i-----
Other Equity-----
Total Shareholders Equity i256.8M230.8M272.9M-31.3M-14.1M
Key Metrics
Total Debt i42.0K274.0K481.0K9.0M10.0M
Working Capital i310.9M229.3M272.3M52.5M18.2M

Balance Sheet Composition

Ars Pharmaceuticals Cash Flow Statement From 2020 to 2024

Metric20242023202220212020
Operating Activities
Net Income i8.0M-54.4M-34.7M-20.2M-1.1M
Depreciation & Amortization i-7.2M-6.8M319.0K213.0K6.0K
Stock-Based Compensation i14.5M9.2M5.8M2.8M3.5M
Working Capital Changes i-12.0M-3.1M-1.3M-2.5M7.0M
Operating Cash Flow i3.3M-55.1M-28.7M-19.5M9.6M
Investing Activities
Capital Expenditures i-563.0K-175.0K-199.0K-55.0K0
Acquisitions i-----
Investment Purchases i-356.0M-272.0M0--
Investment Sales i258.0M185.0M0--
Investing Cash Flow i-106.1M-87.2M-199.0K-55.0K0
Financing Activities
Share Repurchases i-----
Dividends Paid i-----
Debt Issuance i---05.0M
Debt Repayment i-0-8.7M-1.8M-
Financing Cash Flow i69.4M0190.2M53.0M5.0M
Free Cash Flow i13.0M-59.4M-40.3M-17.6M9.1M
Net Change in Cash i-33.4M-142.2M161.2M33.4M14.6M

Cash Flow Trend

Ars Pharmaceuticals Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 168.25
Forward P/E -17.76
Price to Book 6.93
Price to Sales 11.88
PEG Ratio 0.66

Profitability Ratios

Profit Margin -42.74%
Operating Margin -302.95%
Return on Equity -23.56%
Return on Assets -13.85%

Financial Health

Current Ratio 6.17
Debt to Equity 38.28
Beta 0.96

Per Share Data

EPS (TTM) $-0.48
Book Value per Share $1.95
Revenue per Share $1.15

Peer Financial Comparison

CompanyMarket CapP/E RatioP/B RatioROEProfit MarginDebt/Equity
spry1.3B168.256.93-23.56%-42.74%38.28
Vertex 101.3B28.085.9022.77%31.86%8.89
Regeneron 63.6B15.122.0915.34%31.37%9.04
Sarepta Therapeutics 2.0B19.981.46-4.76%-2.34%100.51
Adaptive 2.0B-12.0411.01-57.60%-59.07%121.39
Arcutis 1.9B-13.7813.78-57.33%-35.40%79.27

Financial data is updated regularly. All figures are in the company's reporting currency.